Vestmark Advisory Solutions Inc. Trims Stock Position in Eli Lilly and Company (NYSE:LLY)

Vestmark Advisory Solutions Inc. lessened its stake in Eli Lilly and Company (NYSE:LLY) by 4.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,208 shares of the company’s stock after selling 475 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Eli Lilly and Company were worth $6,534,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Lipe & Dalton acquired a new stake in Eli Lilly and Company during the 4th quarter worth approximately $26,000. Thompson Investment Management Inc. purchased a new position in Eli Lilly and Company in the 3rd quarter valued at $27,000. Legacy Financial Group LLC purchased a new position in Eli Lilly and Company during the 3rd quarter worth $35,000. Optiver Holding B.V. acquired a new stake in shares of Eli Lilly and Company in the 3rd quarter worth $36,000. Finally, Family CFO Inc purchased a new stake in shares of Eli Lilly and Company in the third quarter valued at about $40,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 2.8 %

LLY stock traded down $20.94 during midday trading on Friday, hitting $734.97. 4,595,138 shares of the company’s stock were exchanged, compared to its average volume of 2,629,045. The company has a debt-to-equity ratio of 1.90, a quick ratio of 0.73 and a current ratio of 1.35. Eli Lilly and Company has a one year low of $419.80 and a one year high of $800.78. The stock’s fifty day moving average price is $761.06 and its 200-day moving average price is $671.38. The company has a market cap of $698.52 billion, a PE ratio of 108.24, a price-to-earnings-growth ratio of 1.46 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.62 earnings per share. Research analysts predict that Eli Lilly and Company will post 13.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Wells Fargo & Company boosted their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Morgan Stanley lifted their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a report on Wednesday. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Finally, Barclays lifted their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $757.95.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.